Immunotherapy for breast cancer — who is actually eligible

Most breast cancer patients are not eligible. Immunotherapy has a defined role in a minority of breast cancers, and for the majority it is not part of the plan at all. Your subtype decides it first. Where immunotherapy is considered, it is mainly in triple-negative disease, and even then stage and biomarker testing have to fit.

That is an unusual thing for a cancer clinic to lead with, so it is worth explaining why we do. Breast cancer is the commonest cancer among women in Telangana and Andhra Pradesh, which means an enormous number of families read about immunotherapy every month. Roughly two in three breast cancers are hormone receptor positive. For that group, checkpoint inhibitor immunotherapy is not standard treatment, and no amount of searching will change that. Finding out early saves months of hope pointed in the wrong direction.

The second reason is that breast cancer is a name for several different diseases. Two women can have a lump of the same size in the same place and need completely different treatment, because the cells behave differently. The receptor tests on your biopsy report are what separate them. Those three lines — oestrogen receptor, progesterone receptor, HER2 — do more to decide your treatment than the stage does.

Immunotherapy here means immune checkpoint inhibitors. They do not attack the cancer directly. They aim to release a brake on your own immune cells so those cells can recognise cancer. That approach only makes sense where the immune system already has something to work with, and in breast cancer that is far more often the case in triple-negative disease than in the hormone-driven subtypes.

So this page is not written to talk you into immunotherapy. It is written so that you can look at your own biopsy report and understand, in about two minutes, whether this treatment is even a question for you. At CION, immunotherapy is given as day care at our centres when it is genuinely indicated, and every plan is set by a tumour board rather than by one doctor. Any cost figure discussed with you is indicative, as of August 2026, and is confirmed in writing before treatment starts.

Mainly triple-negative breast cancer. That is the subtype with a defined place for checkpoint inhibitor immunotherapy in international guidelines, in specific early and advanced settings. A small number of patients with any subtype may be considered if tumour testing shows a mismatch repair deficient or microsatellite instability high result.

Proportions above are the broad pattern reported in Indian and international registries and are given to show scale, not to describe your own cancer. They are not outcome figures of any kind. Read them next to your own biopsy report, and ask your oncologist which line you are on. If the report is more than a few months old, or the cancer has come back, the receptor tests may be repeated — a recurrence does not always carry the same receptor pattern as the original tumour.

Being eligible is not the same as being certain to benefit. Immunotherapy helps in a proportion of patients who receive it, and no test available today can tell an individual in advance which group she will be in. Our fuller guide to immunotherapy for triple-negative breast cancer goes through the early and advanced settings one at a time.

Not as standard care. Hormone receptor positive breast cancer is treated with hormone therapy and other established options chosen for that subtype. Checkpoint inhibitor immunotherapy is not a routine part of that plan, and NCCN, ASCO and ESMO do not list it as one. Trials are studying whether it helps selected patients.

This is the answer most readers of this page will get, because hormone receptor positive disease is the largest group. It is worth sitting with for a moment, because it usually lands as bad news and it should not.

Hormone therapy is one of the most established treatments in all of cancer medicine. It is taken as a tablet or given as an injection, it is managed in the outpatient clinic rather than in a day-care chair, and it typically continues for years rather than months. For the right patient it is the workhorse of the whole plan. Immunotherapy is not being withheld from you; it is being left out because your cancer has a better-understood target and there are treatments built specifically to hit it.

A trial existing is also not the same as a treatment being recommended. Trials in India must be approved by an ethics committee and registered with the Clinical Trials Registry – India before anyone is enrolled, and taking part is always voluntary. CION cannot promise anyone a place in a trial, and nothing on this page is a recruitment notice. What is fair to expect from any oncologist is a straight answer about whether a relevant trial exists.

One thing genuinely worth checking: hormone receptor status can change when breast cancer comes back. A cancer that was hormone receptor positive at first diagnosis is occasionally triple-negative on a repeat biopsy of a recurrence, and vice versa. If your disease has recurred, ask whether the receptors were re-tested on the new sample rather than assumed from the old report. It is a short conversation that occasionally changes the entire plan.

Four steps, in this order. Receptor testing on your biopsy defines the subtype. If the cancer is triple-negative and advanced, a PD-L1 test follows. Selected cases also get mismatch repair or microsatellite instability testing. Staging and fitness are then checked before a tumour board confirms the plan.

1. 1

   Receptor testing on the biopsy sample

   Oestrogen receptor, progesterone receptor and HER2. This is done on tissue already taken, needs no extra procedure, and is on your report as ER, PR and HER2. It settles the subtype, and for most patients it settles the immunotherapy question at the same time.

2. 2

   PD-L1 testing, if the cancer is triple-negative and advanced

   Run on the same tissue block and reported as a combined positive score, or CPS. In the early-stage setting before surgery, guidelines do not require a PD-L1 result — the decision there rests on subtype and stage. Turnaround is usually a few working days.

3. 3

   Mismatch repair or microsatellite instability testing, in selected cases

   Uncommon in breast cancer, but worth testing where the pathologist or oncologist suspects it, because a dMMR or MSI-high result can open a door that the subtype alone would have closed.

4. 4

   Stage, general fitness and autoimmune history

   Scans and blood tests confirm the stage. Your team also reviews existing autoimmune conditions, ongoing steroid use and organ transplant history, because these change the risk of immune-related side effects and sometimes rule the treatment out. Response-assessment PET-CT is coordinated at our partner imaging centres.

What a PD-L1 combined positive score band means

A CPS is a measure of how much PD-L1 protein is present, not a prediction of what will happen to you. Scores can differ between laboratories and between samples from the same person, and the scoring system used in breast cancer is not the same one used in other cancers. Our page on what a PD-L1 score means in lung cancer explains the idea in more detail; read it for the principle, and take the actual numbers from a breast specialist. Any cost quoted for biomarker testing is indicative, as of August 2026, and is given in writing before the test is sent.

It means your cancer has a target that other treatments hit more directly. Not being eligible is not a sign that your options are limited or that your care is lesser. Surgery, radiation therapy, chemotherapy, hormone therapy and HER2-directed treatment are all established, and they are chosen for your subtype and stage.

Families often arrive having read that immunotherapy is the newest treatment, and conclude that anything else must be second best. That is not how cancer treatment works. The right treatment is the one matched to the biology of your cancer. Giving a checkpoint inhibitor to a cancer with no immune presence adds side effects and cost with certainty, and benefit only if the evidence supports it.

It is also worth knowing that breast cancer is not unusual in this respect. In lung cancer, immunotherapy is used far more widely, and even there eligibility depends on biomarker testing and a large group of patients does not qualify — our page on who benefits from immunotherapy in lung cancer sets out the same arithmetic for that disease. Across every cancer, immunotherapy is a defined tool for defined situations rather than a general upgrade.

• Ask which subtype you have, in plain words, and ask for it written on your discharge or consultation summary.
• Ask why immunotherapy is not in your plan. A clear answer takes about a minute and should be offered without defensiveness.
• Ask whether your receptor results were re-tested if the cancer has come back.
• Ask what the full plan is, how long it runs, and what it is expected to cost — indicative, as of August 2026, and in writing.
• Ask whether a scheme such as Aarogyasri, CGHS, ECHS or ESI, or your insurance policy, applies to any part of it.

CION is a woman-headed organisation, and breast cancer is the disease our teams see most. Every consultation is 45 minutes, every plan goes to a tumour board, and no test is ordered that will not change a decision. If you have been advised immunotherapy elsewhere and cannot see which line of the subtype table you are on, that is exactly the question a second opinion is for.

Most of the confusion about immunotherapy in breast cancer comes from not knowing which subtype you have. These five questions get you a complete answer in one conversation, whichever way it goes.

• What are my ER, PR and HER2 results, and which subtype do they make this?
• Is immunotherapy an option for that subtype at my stage — yes or no, and why?
• If yes, does my plan need a PD-L1 result first, and has it been sent?
• If no, which treatment is doing the work in my plan instead, and for how long?
• What is the estimated cost of the full plan, and what will insurance or a government scheme cover?

Related reading

• Immunotherapy for Triple-Negative Breast Cancer — the next page to read if your report says triple-negative, covering the early and advanced settings separately.
• PD-L1 Testing in Lung Cancer: What Your Score Means — the clearest explanation of how PD-L1 scoring works, useful for the principle even though the breast scoring system differs.
• Immunotherapy for Lung Cancer: Who Benefits and How Much — how eligibility is decided in the cancer where immunotherapy is used most, and why a large group still does not qualify.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care, how response scans are coordinated with our partner imaging centres, and how costs are set out in writing.

If you would rather not work through this alone, bring your biopsy report to a consultation. Forty-five minutes with a medical oncologist, and a tumour board review afterwards, will tell you which line of that subtype table you are on and what follows from it.

This page is general information and does not replace a consultation. It describes treatment classes only, not specific medicines or brands, and it recommends no treatment. Eligibility criteria, subtype proportions and biomarker thresholds are drawn from NCCN, ASCO and ESMO patient-education guidance current in August 2026 and can change; no outcome or survival figure of any kind is stated or implied. Every decision about your treatment belongs with your own treating team.

Get a second opinion on your breast cancer plan

Free, written, and reviewed by our tumour board — so you know why each treatment is in your plan and why the others are not.